Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Other Working Capital Changes: 2018-2024

Historic Other Working Capital Changes for Silence Therapeutics (SLN) over the last 7 years, with Dec 2024 value amounting to $457,998.

  • Silence Therapeutics' Other Working Capital Changes fell 679.39% to -$5.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$7.2 million, marking a year-over-year decrease of 124.52%. This contributed to the annual value of $457,998 for FY2024, which is 104.44% up from last year.
  • Per Silence Therapeutics' latest filing, its Other Working Capital Changes stood at $457,998 for FY2024, which was up 104.44% from -$10.3 million recorded in FY2023.
  • In the past 5 years, Silence Therapeutics' Other Working Capital Changes registered a high of $457,998 during FY2024, and its lowest value of -$10.3 million during FY2023.
  • For the 3-year period, Silence Therapeutics' Other Working Capital Changes averaged around -$5.1 million, with its median value being -$5.4 million (2022).
  • As far as peak fluctuations go, Silence Therapeutics' Other Working Capital Changes plummeted by 93,708.86% in 2020, and later soared by 104.44% in 2024.
  • Silence Therapeutics' Other Working Capital Changes (MRY) stood at -$4.8 million in 2020, then soared by 74.04% to -$1.2 million in 2021, then plummeted by 337.61% to -$5.4 million in 2022, then plummeted by 89.66% to -$10.3 million in 2023, then skyrocketed by 104.44% to $457,998 in 2024.
  • Its Other Working Capital Changes was $457,998 in FY2024, compared to -$10.3 million in FY2023 and -$5.4 million in FY2022.